title: Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.
abstract: Inverse associations of Parkinson's disease (PD) with cigarette smoking, coffee drinking, and nonsteroidal anti-inflammatory drug (NSAID) use have been reported individually, but their joint effects have not been examined. To quantify associations with PD for the individual, two-way and three-way combinations of these factors, a case-control association study with 1,186 PD patients and 928 controls was conducted. The study setting was the NeuroGenetics Research Consortium. Subjects completed a structured questionnaire regarding smoking, coffee, and NSAID consumption. Odds ratios were calculated using unconditional logistic regression. Smoking, coffee, and over the counter NSAID use as individual factors exhibited significantly reduced risks of 20% to 30%. The two-way and three-way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. Smoking and coffee exhibited significant inverse risk trends with increasing cumulative exposures, suggesting dose-response relations. With respect to the combination of all three exposures, persons who were at the highest exposure strata for smoking and coffee and used NSAIDs had an estimated 87% reduction in risk (OR = 0.13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated.
authors.affiliation: Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA.
authors.forename: Karen M
authors.initials: KM
authors.lastname: Powers
authors.forename: Denise M
authors.initials: DM
authors.lastname: Kay
authors.forename: Stewart A
authors.initials: SA
authors.lastname: Factor
authors.forename: Cyrus P
authors.initials: CP
authors.lastname: Zabetian
authors.forename: Donald S
authors.initials: DS
authors.lastname: Higgins
authors.forename: Ali
authors.initials: A
authors.lastname: Samii
authors.forename: John G
authors.initials: JG
authors.lastname: Nutt
authors.forename: Alida
authors.initials: A
authors.lastname: Griffith
authors.forename: Berta
authors.initials: B
authors.lastname: Leis
authors.forename: John W
authors.initials: JW
authors.lastname: Roberts
authors.forename: Erica D
authors.initials: ED
authors.lastname: Martinez
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Montimurro
authors.forename: Harvey
authors.initials: H
authors.lastname: Checkoway
authors.forename: Haydeh
authors.initials: H
authors.lastname: Payami
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D002110:Caffeine / Q000008:administration & dosage / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D003069:Coffee; D003071:Cognition / Q000187:drug effects*; D004327:Drinking Behavior; D005260:Female; D006801:Humans; D008297:Male; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology*; D010300:Parkinson Disease / Q000453:epidemiology / Q000503:physiopathology* / Q000517:prevention & control*; D015995:Prevalence; D012907:Smoking / Q000453:epidemiology*; D011795:Surveys and Questionnaires
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000697:Central Nervous System Stimulants; D003069:Coffee; D002110:Caffeine; D009538:Nicotine